These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 11904965)
1. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients]. Kubo O; Takakura K Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965 [TBL] [Abstract][Full Text] [Related]
2. Antigen related to cell proliferation in malignant gliomas recognized by a human monoclonal antibody. Kokunai T; Tamaki N; Matsumoto S J Neurosurg; 1990 Dec; 73(6):901-8. PubMed ID: 2230972 [TBL] [Abstract][Full Text] [Related]
3. [Anti-TA226 human monoclonal antibody (ACA-11) against glioma]. Kokunai T Nihon Rinsho; 2002 Jan; 60(1):100-6. PubMed ID: 11808318 [TBL] [Abstract][Full Text] [Related]
4. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. Lee Y; Bigner DD Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097 [TBL] [Abstract][Full Text] [Related]
5. [Experimental study on immunotherapy of meningeal gliomatosis with monoclonal antibody]. Yamashita Y; Takahashi H; Nakazawa S No To Shinkei; 1993 Jan; 45(1):63-70. PubMed ID: 8476656 [TBL] [Abstract][Full Text] [Related]
7. [Advances of BRM therapy of malignant brain tumors]. Nagai M Gan To Kagaku Ryoho; 1991 Feb; 18(2):188-94. PubMed ID: 1992912 [TBL] [Abstract][Full Text] [Related]
8. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
9. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies: prospects for specific immunotherapy for gliomas. Nowak TP Am J Clin Oncol; 1987 Aug; 10(4):278-80. PubMed ID: 3113229 [TBL] [Abstract][Full Text] [Related]
11. Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. Glassy MC; Hagiwara H Hum Antibodies; 2009; 18(4):127-37. PubMed ID: 19996527 [TBL] [Abstract][Full Text] [Related]
12. Cell- and peptide-based immunotherapeutic approaches for glioma. Yamanaka R Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264 [TBL] [Abstract][Full Text] [Related]
13. Cancer vaccines: an update with special focus on ganglioside antigens. Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591 [TBL] [Abstract][Full Text] [Related]
15. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas. Mitra S; Li G; Harsh GR Neurosurg Clin N Am; 2010 Jan; 21(1):67-76. PubMed ID: 19944967 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for human glioma: innovative approaches and recent results. Hussain SF; Heimberger AB Expert Rev Anticancer Ther; 2005 Oct; 5(5):777-90. PubMed ID: 16221048 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of local immunoresistance in glioma. Albesiano E; Han JE; Lim M Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963 [TBL] [Abstract][Full Text] [Related]
19. Autologous natural killer cell therapy for human recurrent malignant glioma. Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367 [TBL] [Abstract][Full Text] [Related]
20. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]